Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine.
Rui KitadaiTatsunori ShimoiShu YazakiHitomi Sumiyoshi OkumaMai HoshinoMunehiro ItoAyumi SaitoShosuke KitaYuki KojimaTadaaki NishikawaKazuki SudoEmi NoguchiYasuhiro FujiwaraMasayuki YoshidaKan YonemoriPublished in: Breast cancer (Tokyo, Japan) (2024)
Eribulin and capecitabine sensitivity may vary based on HER2 expression in patients with HER2-low and HER2-null breast cancer. Prognosis was similar between the HER2-low and the HER2-null groups.